AACR 2021 | Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, outlines updated data from the Phase III IMvigor 130 trial (NCT02807636) of atezolizumab as monotherapy or in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. Patients who received atezolizumab plus chemotherapy had improved overall survival at 13 months of follow-up, however, this was not statistically significant. Patients who received atezolizumab monotherapy and were PD-L1 positive had improved overall survival. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Dr Grande has received honoraria for speaker engagements, advisory roles, or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma and Thermo Fisher Scientific; and has received research grants from Astellas, Astra Zeneca, IPSEN, Lexicon, MTEM/Threshold, Nanostring Technologies, Pfizer and Roche.
